Series 2 Paper VII - THC Is a Poor Proxy for Endocannabinoid Medicine

Delta 9 tetrahydrocannabinol is widely treated as a practical proxy for supporting the endocannabinoid system. This assumption collapses a complex regulatory architecture into single receptor stimulation and obscures critical physiological distinctions. The endocannabinoid system is an adaptive, feedback governed signalling network characterised by demand driven ligand synthesis, spatial specificity, enzymatic termination, and proportional modulation across neural, immune, metabolic, endocrine, and cardiovascular domains. Endogenous ligands are produced in response to perturbation and are rapidly degraded, preserving temporal precision and regulatory flexibility. Exogenous tetrahydrocannabinol operates according to a different control logic. It is systemically distributed, persistently engages CB1 receptors, and functions independently of endogenous timing constraints. Under repeated exposure, compensatory receptor adaptation, intracellular signalling recalibration, endocrine threshold shifts, metabolic storage bias, and immune modulation may emerge. These changes reflect allostatic restructuring rather than restoration of physiological balance. This manuscript advances a structural distinction between physiological endocannabinoid support and chronic receptor dominance. Supporting a regulatory system requires preservation of feedback integrity, reversibility, and adaptive range. Sustained exogenous forcing may provide short term symptom relief while progressively narrowing regulatory bandwidth, particularly in metabolically, autonomically, immunologically, or developmentally vulnerable states. Receptor stimulation is not synonymous with systemic repair. A regulation first framework for cannabinoid therapeutics is therefore required. Such a framework must be indication specific, time aware, and system informed, recognising that adaptive capacity, not perceptual quieting, is the primary marker of restored physiological coherence.